10 sep 25   ekf diagnostics hldg - notice of interim results ekf diagnostics holdings plc | ekf | 29.9 0 0.0% | mkt cap: 134.3m    rns number : 6761y ekf diagnostics holdings plc 10 september 2025     ekf diagnostics holdings plc ("ekf" or the "company", or the "group")   notice of interim results investor presentation                                                                                                                                                               ekf diagnostics holdings plc (aim: ekf), the aim-quoted global diagnostics business, confirms it will announce its interim results for the six months ended 30 june 2025 on tuesday 16 september.     investor presentation ekf diagnostics will be hosting a live online presentation open to all existing and potential investors on tuesday 16 september 2025 at 10.30am (bst), via the investor meet company platform. investors can sign up to investor meet company for free and add to meet ekf diagnostics via:   https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor   investors who already follow ekf on the investor meet company platform will automatically be invited.   a recording of the presentation, a pdf of the slides used, and responses to the q&a session will be available on the investor meet company platform afterwards.   ekf diagnostics holdings plc www.ekfdiagnostics.com julian baines, executive chair  via walbrook pr gavin jones, chief executive officer   stephen young, chief financial officer   singer capital markets (nominated adviser & broker) tel: +44 (0)20 7496 3000 phil davies / oliver platts    walbrook pr limited tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com paul mcmanus / alice woodings  mob: +44 (0)7980 541 893 / +44 (0)7407 804 654     about ekf diagnostics holdings plc (www.ekfdiagnostics.com)   ekf is an aim-listed global diagnostics business focussed on:   ● point-of-care analysers in the key areas of hematology and diabetes  ● life sciences offers contract fermentation services for clinically important enzymes and proteins, and the manufacture of beta-hydroxybutyrate (β-hb), used as a quantitative ketone test to identify patients suffering from diabetic ketoacidosis, as well as in many other clinical applications.   ekf has headquarters in penarth (near cardiff) and operates five manufacturing sites across the us and germany, selling into over 120 countries world-wide.     this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   nordklfbeklxbbe return to news summary

Label: Neutral